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Abstract: Background: Interleukin (IL)-17 is the main Th-1 cytokine, produced by activated T-lymphocytes.
The potential IL-17 value in rheumatoid arthritis (RA) pathogenesis consists of its independent inflamma-
tory response induction and mediated stimulation of proinflammatory factors synthesis resulting in joint
destruction. The aim of study was to determine the role of IL-17 in immuno-inflammatory/autoimmune
reactions development and to reveal IL-17 serum level associations with clinical and immunological char-
acteristics of RA. Methods: 50 patients with early RA (disease duration < 12 month) and 15 healthy
individuals were examined. All patients underwent complex clinical and laboratory examination. The
immunological investigation included lymphocyte count and its subpopulative composition determination
using monoclonal antibodies; detection of circulative immune complex level was done by Digeon method,
IgG, IgM, IgA - by Manchini method. The serum concentrations of CRP(DAI, USA), sCD40L, matrix
metalloproteinases (MMP)-3 (Bender MedSystems, Austria), IL-17 (Biosource, Belgium), rheumatoid
factor (RF) («Vektorbest», Russia), anti-CCP antibodies (Axies-Shield Diagnostic, UK) were revealed
using ELISA immunoassay. Results: On the base of IL-17 serum level patients were divided in two
groups: group1 (n = 28) were patients with normal IL-17 serum level and group2 (n = 22) were those
with high IL-17 serum level. In the group2, the rate of patients’ pain assessment by visual analogue scale
(67.3 ± 7.2 vs 32.8 ± 4.6; P < 0.001), tender (16.7 ± 2.0 vs 8.4 ± 1.1; P < 0.01) and swollen (12.3 ± 2.3
vs 3.9 ± 0.8; P < 0.01) joint count, DAS28 (5.0 ± 0.4 vs 2.8 ± 0.2 P < 0.01) were significantly higher
compare to group1. It was found that in group2 the higher T-lymphocyte amount (CD3) was due to CD4
higher quantity, at the same time CD8 amount was significantly lower (22.2 ± 1.5% vs 28.4 ± 1.7%, P
< 0.05) compare to group1. This caused the immunoregulative index increasing and indicated in the lost
of autoimmune process regulation, including B-lymphocytes (CD19) activation. The CD154 expression
was significantly lower in the group2 (3.4 ± 0.4% vs 10.8 ± 2.8%, P < 0.05) compare to group1. The
difference in autoimmune reaction indices wasn’t significant between groups except antibody-producing
B-lymphocytes (13.7 ± 1.5% vs 8.5 ± 1.0%, P < 0.05) and IgM RF serum level (2.9 ± 0.3 U/ml vs
1.6 ± 0.5 U/ml, P < 0.05), which were significantly higher in group1. The IL-17 level had a positive
correlative connections with DAS28 (r = 0.7; P < 0.05), circulative immune complex level (r = 0.38; P
< 0.05), anti-CCP antibodies (r = 0.4; P < 0.05), IgM RF (r = 0.41; P < 0.05), CD4 (r = 0.38; P <
0.05) and negative correlative connection with CD8 (r = -0.39; P < 0.05). Conclusions: The importance
of IL-17 value in immuno-inflammatory and autoimmune reactions development through T-lymphocytes
activation in RA pathogenesis was confirmed. Thus the influence on T-depended immuno-inflammatory
reaction products synthesis could be a new therapeutic target of RA patients’ management. Disclosure
statement: All authors have declared no conflicts of interest
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OP59. THE VALUE OF INTERLEUKIN-17 SERUM LEVEL IN
RHEUMATOID ARTHRITIS IMMUNOPATHOGENESIS
Iuliia V. Biliavska and Oleg P. Bortkevych
Noncoronarogenic diseases of myocardium and clinical rheumatol-
ogy, National scientific center ‘Acad. M.D. Strazhesko Institute of
Cardiology’, Kyiv, Ukraine
Background: Interleukin (IL)-17 is the main Th-1 cytokine, produced
by activated T-lymphocytes. The potential IL-17 value in rheumatoid
arthritis (RA) pathogenesis consists of its independent inflammatory
response induction and mediated stimulation of proinflammatory
factors synthesis resulting in joint destruction. The aim of study was
to determine the role of IL-17 in immuno-inflammatory/autoimmune
reactions development and to reveal IL-17 serum level associations
with clinical and immunological characteristics of RA.
Methods: 50 patients with early RA (disease duration <12 month) and
15 healthy individuals were examined. All patients underwent complex
clinical and laboratory examination. The immunological investigation
included lymphocyte count and its subpopulative composition
determination using monoclonal antibodies; detection of circulative
immune complex level was done by Digeon method, IgG, IgM, IgA - by
Manchini method. The serum concentrations of CRP(DAI, USA),
sCD40L, matrix metalloproteinases (MMP)-3 (Bender MedSystems,
Austria), IL-17 (Biosource, Belgium), rheumatoid factor (RF)
(«Vektorbest», Russia), anti-CCP antibodies (Axies-Shield Diagnostic,
UK) were revealed using ELISA immunoassay.
Results: On the base of IL-17 serum level patients were divided in two
groups: group1 (n¼ 28) were patients with normal IL-17 serum level
and group2 (n¼22) were those with high IL-17 serum level. In the
group2, the rate of patients’ pain assessment by visual analogue scale
(67.37.2 vs 32.84.6; P< 0.001), tender (16.72.0 vs 8.41.1;
P<0.01) and swollen (12.32.3 vs 3.9 0.8; P<0.01) joint count,
DAS28 (5.0 0.4 vs 2.80.2 P<0.01) were significantly higher
compare to group1.
It was found that in group2 the higher T-lymphocyte amount (CD3)
was due to CD4 higher quantity, at the same time CD8 amount was
significantly lower (22.21.5% vs 28.41.7%, P< 0.05) compare to
group1. This caused the immunoregulative index increasing and
indicated in the lost of autoimmune process regulation, including B-
lymphocytes (CD19) activation. The CD154 expression was signifi-
cantly lower in the group2 (3.4 0.4% vs 10.82.8%, P< 0.05)
compare to group1. The difference in autoimmune reaction indices
wasn’t significant between groups except antibody-producing B-
lymphocytes (13.71.5% vs 8.51.0%, P< 0.05) and IgM RF serum
level (2.9 0.3 U/ml vs 1.60.5 U/ml, P<0.05), which were signifi-
cantly higher in group1. The IL-17 level had a positive correlative
connections with DAS28 (r¼0.7; P< 0.05), circulative immune com-
plex level (r¼0.38; P<0.05), anti-CCP antibodies (r¼0.4; P<0.05),
IgM RF (r¼0.41; P<0.05), CD4 (r¼0.38; P<0.05) and negative
correlative connection with CD8 (r¼ -0.39; P<0.05).
Conclusions: The importance of IL-17 value in immuno-inflammatory
and autoimmune reactions development through T-lymphocytes
activation in RA pathogenesis was confirmed. Thus the influence on
T-depended immuno-inflammatory reaction products synthesis could
be a new therapeutic target of RA patients’ management.
Disclosure statement: All authors have declared no conflicts of
interest.
OP60. DEFECTIVE CD3þCD8þCD28 SUPPRESSOR
FUNCTION IN RA PATIENTS IS PARTIALLY RESTORED AFTER
ANTI-TNFa INHIBITOR THERAPY AND MAY BE ASSOCIATED
WITH REDUCED ICOS AND PD-1 EXPRESSION
Sabrina Ceeraz1, Jo Spencer2, Ernest H. Choy1 and Valerie Corrigall1
1Academic Department of Rheumatology, Centre of Molecular and
Cellular Biology of Inflammation, King’s College London, London,
UK; 2Department of Immunobiology, King’s College London,
London, UK
Background: Immunoregulatory mechanisms in rheumatoid arthritis
(RA) are present but may be deficient and unable to suppress
persistent inflammation in the joints. CD3þCD8þCD28-T cells have
been shown to have suppressor function which may be compromised
in autoimmune disease. Previously we have demonstrated that the
function of CD3þCD8þCD28- cells is deficient in RA patients. In this
study, we aimed to determine whether treatment by tumour necrosis
factor alpha (TNFa) inhibitors may re-establish their defective
regulatory function.
Methods: Heparinized blood samples from age-matched healthy
controls (HC), osteoarthritis (OA) patients, RA patients on methotrexate
(RAMTX) and RA patients on anti-TNFa therapy (RATNF) were
collected and four colour flow cytometry was performed to determine
the percentage of CD3þCD8þCD28- cells in the peripheral blood.
Functional characterization of the CD3þCD8þCD28- cells followed
negative isolation of these cells using immunomagentic beads
(purity¼ 97%). The cells were cocultured with autologous peripheral
blood mononuclear cells (PBMC) at the ratio 1:1 in the presence of
anti-CD3 antibody for 72 h and cell proliferation was determined by
tritiated thymidine incorporation. The surface expression of ICOS and
PD-1 on CD3þCD8þCD28- cells was determined after 48 h stimula-
tion with anti-CD3 antibody.
Results: RAMTX patients showed significantly increased percentages
of CD3þCD8þCD28 cells (687%, n¼46) compared with OA
patients (55.415%, n¼17, P¼0.05), HC (45.38%, n¼15,
P¼0.04) and RATNF patients (47.4 15%, n¼ 21, P¼0.04).
Functional assays demonstrated that the addition of CD3þ CD8þ
CD28 cells to autologous PBMC (ratio 1:1) resulted in significant
suppression of PBMC proliferation to anti-CD3 antibody stimulation in
HC (45.311% inhibition, P¼0.03) but not in the RAMTX cultures
(1.52% inhibition). In contrast, RATNF CD3þCD8þCD28 cells
significantly suppressed PBMC proliferation (30 19% inhibition,
P¼0.05). Further investigation of the mechanism whereby RAMTX
cells fail to suppress showed that significantly fewer cells in the anti-
CD3 stimulated CD3þCD8þCD28-cell population from RAMTX
patients expressed ICOS (2.02%, RAMTX vs 8.73.2%, HC;
n¼ 10 RAMTX/HC, P<0.0001) and PD-1 (2.3 3%, RAMTX vs
9.52%, HC; P<0.0001). Similar studies for RATNF patients are
ongoing with preliminary data indicating that in some RATNF patients,
the expression of PD-1 is partially restored (5.43%; n¼5).
Conclusions: This study indicates that although the percentage of
CD3þCD8þCD28 cells is higher in RAMTX patients, they have
deficient suppressor function, which may be restored following TNFa
inhibitor therapy. This impaired suppressor activity may be related to
cell surface expression of ICOS and PD-1.
Disclosure statement: All authors have declared no conflicts of
interest.
OP61. RHEUMATOID SYNOVIAL FIBROBLASTS SUPPORT
AID EXPRESSION AND IG CLASS-SWITCHING IN B CELLS VIA
A BAFF-DEPENDENT TLR3-STIMULATED PATHWAY
Michele Bombardieri1, Yvonne Ngar Woon Kam1, Fabia Brentano2,
Ken Choi1, Diego Kyburz2, Steffen Gay2, Iain B. McInnes3 and
Costantino Pitzalis1
1Queen Mary University of London, William Harvey Research
Institute, Centre for Experimental Medicine and Rheumatology,
London, UK; 2University Hospital Zu¨rich Department of
Rheumatology, Zurich, Switzerland; 3Glasgow Biomedical Research
Centre, University of Glasgow, Glasgow, UK
Background: Rheumatoid arthritis (RA) is characterized by the
presence of synovial niches of autoreactive B cells which express
activation-induced cytidine deaminase (AID), the enzyme initiating Ig
class-switching (CSR) and sustain in situ autoantibody. Importantly, B
cell niches remain functional in the RA-SCID model in the absence of
recirculating cells, suggesting that autocrine mechanisms support
ongoing B cell activation in the RA synovium. Here we investigated
whether RA synovial fibroblasts (RASF), which are known to contribute
to RA synovitis, are capable of directly regulating B cell activation, AID
expression and CSR. In addition, we dissected the molecular basis of
stromal cell/B cell interactions with particular emphasis on the role of
toll-like receptors (TLRs) signaling and B cell survival/proliferation
factors.
Methods: mRNA and protein expression of B cell survival factors
BAFF and APRIL in RASF and OASF stimulated with TLR2, TLR3 and
TLR4 ligands was assessed by Taqman PCR (QT-PCR) and ELISA,
respectively. Un-switched IgDþ B cells were isolated from human
tonsils using magnetic cell sorting. Isolated B cells were co-cultured
via transwell or cell-cell contact with RASF/OASF for 24 h and 72 h in
the presence or absence of TLR ligands and with or without BCMA-Ig
as a blocker of soluble BAFF/APRIL. AID mRNA expression and
IgM/A/G production were measured to assess functional activation of
B cells. In addition, I-C and Ia-C circular transcripts (CT, molecular
by-products of ongoing CSR from IgM to IgG and IgM to IgA,
respectively) were assessed by rt-PCR.
Results: In vitro stimulation of TLR3 and to a significantly lesser
extent TLR4, but not TLR2 on RASF led to strong induction of BAFF
(	1,000-fold increase with TLR3) and APRIL mRNA expression. In
response to TLR3, BAFF was time-dependently released in the
supernatant of RASF (	300 pg/ml) and, to a lesser extent, OASF.
TLR3 stimulation of RASF in co-culture with B cells strongly enhanced
AID expression, ongoing CSR to IgG, but not IgA, as shown by
detection of I-C CT and release of IgG. By contrast, TLR3
stimulation alone had no direct effect on B cells. Conversely, blockade
of soluble BAFF/APRIL by BCMA-Ig inhibited TLR3-induced RASF-
dependent production of AID mRNA, I-C CT as well as the secretion
of IgG.
Conclusions: We demonstrated that RASF are able to release high
levels of B cell survival factors upon TLR3 stimulation at both mRNA
and protein level. The release of these factors was functional, as
demonstrated by the capacity of RASF to directly modulate AID
expression, CSR and production of class-switched antibodies in
co-cultured un-switched B cells. This effect was abrogated by
blockade of soluble BAFF and APRIL. Overall, these data strongly
support a fundamental role for TLR3-dependent release of BAFF and
APRIL by RASF in sustaining functional B cell activation and antibody
production.
Disclosure statement: All authors have declared no conflicts of
interest.
OP62. QUANTIFYING IN VIVO FLUORESCENCE IMAGING IN
MURINE ARTHRITIS BY TARGETING E-SELECTIN
Luke L. Gompels1, Tonia Vincent1, Leigh Madden1, Ngee H. Lim1,
Ellen McConnell2, Kay Mcnamee1, Dorian O. Haskard2 and Ewa
M. Paleolog1
1Kennedy Institute of Rheumatology, Imperial College, London, UK;
2Eric Bywaters Centre, National Heart and Lung Institute, Imperial
College, London, UK
Background: In vivo molecular optical imaging can delineate at the
macroscopic level biologic processes that are occurring at the cellular
and molecular level. E-Selectin, a leucocyte adhesion molecule
expressed on activated endothelium, is upregulated by TNFa and
increased in RA. Furthermore, radiolabelled F(ab’)2 fragment of anti-E-
Selectin monoclonal antibody demonstrates increased specificity
compared with conventional technetium-oxidronate scanning in
patients with RA. Collagen-induced arthritis (CIA), an animal model
of RA, has been widely used to study the pathogenesis of arthritis and
to identify new therapies for RA, including anti-TNFa. Pro-inflammatory
cytokines, such as TNFa and IL-1b, are expressed in the arthritic joints
of both murine CIA and RA. This study aimed to demonstrate and
quantify E-Selectin targeted fluorescent imaging in vivo in a model of
paw inflammation following local injection of murine TNFa and
subsequently in CIA as a model of RA.
Methods: Anti-murine E-selectin and isotype control antibodies were
cultured from hybridoma cell lines and labelled with Dylight 750 nm
near-infra red probe (excitation/emission spectra of 752 nm/778 nm).
Specificity of antibody binding to recombinant murine E-selectin pre-
and post-labelling was confirmed by ELISA. Paw inflammation was
induced by the intraplantar injection of murine TNF (50 ng). CIA was
induced by an intradermal injection of bovine type II collagen (100g)
emulsified in complete Freund’s adjuvant. Following injection of
labelled antibodies animals were imaged using a Kodak FX Pro
Optical in vivo imaging system.
Results: Mean fluorescence intensity was measured over the time
course of TNFa-induced inflammation and demonstrated a 1.98 fold
increase (P< 0.01) in signal at 8 h following injection of anti-E-selectin
antibody compared with isotype control in inflamed paws. E-selectin
signal was significantly abrogated by pre-treatment with etanercept
(P<0.05 vs untreated). Fluorescence was also measured in the in the
CIA model and showed a reduction in E-Selectin mean fluorescent
signal intensities from 11220 2225 (n¼ 4) in mice with established
arthritis, to 6188787 (n¼6; P<0.05) following etanercept treatment.
Immunohistochemical analyses confirmed that E-Selectin expression
can be detected following induction of arthritis in the CIA model at
early, mid and late time points of arthritis.
Conclusions: Targeted in vivo optical imaging in TNFa induced paw
oedema is a quantifiable molecular imaging technique that delineates
increased signal due to E-selectin upregulation in the inflamed paw.
The TNF inhibitor etanercept significantly abrogated signal in CIA. The
differential distribution of E-Selectin targeted signal into inflamed
tissue compared with non-specific IgG may enhance drug targeting.
Novel hardware technology and highly innovative reporter probes and
dyes have potential for translating into future molecular imaging
techniques for patients with arthritis.
Disclosure statement: All authors have declared no conflicts of
interest.
OP63. TSG-6: AN AUTOCRINE REGULATOR OF
INFLAMMATORY JOINT DISEASE?
Catherine Swales1, David J. Mahoney1, Nicholas A. Athanasou1,
Michele Bombardieri2, Costantino Pitzalis2, Omar Sharif3, Anthony
J. Day4, Caroline M. Milner4 and Afsie Sabokbar1
1Nuffield Department of Orthopaedics, Rheumatology and
Musculoskeletal Sciences, Botnar Research Centre, Oxford, UK;
2Department of Experimental Medicine and Rheumatology, William
Harvey Research Institute, London, UK; 3Department of Anatomy,
University of Bristol, Bristol, UK; 4Wellcome Trust Centre for Cell-
Matrix Research, University of Manchester, Manchester, UK
Background: TSG-6, the secreted product of TNF-stimulated gene 6,
is present in the cartilage, synovium and synovial fluids of RA patients.
It is constitutively expressed by RA synoviocytes, where its production
is up-regulated by TNFa, IL-1 and IL-17. Animal models indicate a
protective role for TSG-6 in inflammatory joint disease, with evidence
of both anti-inflammatory and chondroprotective effects in mice with
collagen- and antigen-induced arthritis. Recent in vitro studies have
indicated an additional anti-resorptive effect of TSG-6, possibly via an
interaction with RANKL, the major regulator of osteoclastogenesis.
TSG-6 has a similar potency to OPG (the soluble decoy receptor for
RANKL) but, unlike OPG, inhibits only osteoclast activation and not
formation. The fully-humanized monoclonal antibody against RANKL,
denosumab, has been shown to reduce erosion scores in clinical trials
of RA, but its utility may be diminished by its lack of anti-inflammatory
properties. This study sought to determine whether (i) TSG-6 acts
synergistically with OPG in inhibiting osteoclastic bone resorption, (ii)
TSG-6 is produced during cytokine-mediated osteoclastogenesis and
(iii) TSG-6 can regulate the process of osteoclastogenesis in patients
with inflammatory joint disease.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated
from healthy volunteers; synovial fluid (SF) macrophages were derived
from patients with inflammatory and non-inflammatory joint disease
and synovial tissue samples were derived from biopsy and arthroplasty
specimens. PBMCs and SF macrophages were cultured in the
presence or absence of inflammatory mediators (TNFa, IL-1, IL-6
and IL-17) TSG-6 andOPG. Osteoclast formation was assessed
by TRAP staining and osteoclast activity by lacunar resorption. TSG-6
release in cell culture media by osteoclast precursors and mature
osteoclasts was measured using ELISA. TSG-6 expression in synovial
tissue was assessed immunohistochemically.
Results: Our data show that:
1) TSG-6 is expressed by osteoclasts and in the synovium of RA
patients; 2) TSG-6 and OPG have synergistic effects on the inhibition
of RANKL-mediated bone resorption; 3) the inflammatory cytokines
TNFa, IL-1 and IL-6 but not IL-17 induce TSG-6 production by
osteoclast precursors (PBMCs) and 4) induction of TSG-6 expression
in PBMCs correlates with an inhibition of osteoclast-mediated lacunar
resorption, suggesting an autocrine control of osteoclast activity by
TSG-6.
Conclusions: In the presence of inflammatory cytokines, osteoclast
precursors produce TSG-6 at concentrations that are sufficient to
inhibit osteoclast activity and reduce lacunar resorption. This may
represent an autocrine mechanism to limit the degree of bone
resorption during joint inflammation. Although in the complex
milieu of inflammatory synovial fluid, this mechanism is insufficient
to prevent local erosion, the chondroprotective, anti-inflammatory
and anti-resorptive effects of TSG-6 make it a potential therapeutic
option.
Disclosure statement: All authors have declared no conflicts of
interest.
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OP64. OSTEOCLAST-MEDIATED BONE RESORPTION:
REGULATION BY HYPOXIA-INDUCIBLE FACTOR (HIF) AND
ANGIOPOIETIN-LIKE 4 (ANGPTL4)
Helen Knowles1, Anne-Marie Cleton-Jansen2, Eberhard Korsching3
and Nick Athanasou1
1Nuffield Department of Orthopaedics Rheumatology and
Musculoskeletal Sciences, University of Oxford, Oxford, UK;
2Department of Pathology, Leiden University Medical Centre, Leiden,
Netherlands; 3Pathology Institute, University of Munster, Munster,
Germany
Background: Hypoxia is a feature of the hyperplastic synovium in
rheumatoid arthritis (RA). Many cellular components of RA express the
hypoxia-inducible transcription factor, HIF. We have recently demon-
strated that osteoclast-mediated bone resorption is enhanced by
hypoxia in a HIF-1a-dependent manner (1). We continue our
investigation of the molecular mechanisms regulating hypoxia-induced
osteoclast activation to further understanding of bone resorption in RA.
Methods: Osteoclasts were differentiated from CD14þPBMC with M-
CSF (25 ng/ml) and RANKL (50 ng/ml) for 16 days. Osteoclasts were
then exposed to hypoxia (2% O2) for 24 h prior to fixation, analysis of
resorption (toluidine blue staining of dentine slices) or collection of
RNA, protein or cell supernatant. To identify potential genes of interest,
an Illumina HumanWG-6 v3.0 48k array was performed comparing 6
paired samples of normoxic vs hypoxic osteoclasts. Transfection of
mature osteoclasts with siRNA against HIF-1a or HIF-2a was
performed using RNAiMAX (Invitrogen).
Results: Use of a panel of normoxic inducers of HIF (CoCl2,
desferrioxamine, dimethyloxalyl glycine, L-mimosine) revealed that
HIF expression is sufficient to enhance osteoclast resorption in the
absence of a hypoxic stimulus. Analysis of microarray data therefore
focussed on known HIF target genes.
ANGPTL4 is a HIF-regulated gene and putative endocrine signalling
molecule involved in lipid and glucose metabolism. A potential role in
osteoclast resorption was postulated based on known associations
with MMP expression and cartilage degradation (2) and over-
expression in RA (3). We have confirmed time- and O2 concentra-
tion-dependent upregulation of ANGPTL4 in osteoclasts and osteo-
blasts by real-time PCR, Western blotting and ELISA. ANGPTL4
expression was also increased by normoxic inducers of HIF.
Exogenous ANGPTL4 (25–100 ng/ml) caused a 2.5-fold increase in
osteoclastic bone resorption. It could also partially correct the
inhibition of hypoxic induction of osteoclast activity caused by
transfection of mature osteoclasts with HIF-1a siRNA. However,
ANGPTL4 had no effect on either osteoclast differentiation from
monocytic precursors, or on monocyte survival / proliferation.
Conclusions: These data demonstrate that expression of HIF is
sufficient to stimulate osteoclast-mediated bone resorption in the
absence of a hypoxic stimulus. ANGPTL4 is at least partially able to
compensate for HIF-1a deficiency with respect to stimulation of
osteoclast activity. This is the first description of a role(s) for ANGPTL4
in osteoclast biology and represents a potential mechanism whereby
HIF could regulate bone resorption in the RA microenvironment.
Disclosure statement: All authors have declared no conflicts of
interest.
Concurrent Oral 10 – Connective Tissue
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OP65. MOLECULAR AND CELLULAR EVOLUTION OF
FUNCTIONAL TERTIARY LYMPHOID STRUCTURES IN
SALIVARY GLANDS OF NOD MICE
Elisa Astorri1, Michele Bombardieri1, Elisa Corsiero1, Silvia Gabba1,
Francesca Barone2, Gordon Proctor3 and Costantino Pitzalis1
1Centre for Experimental Medicine and Rheumatology, William
Harvey Research Institute, Queen Mary University, London, UK;
2Department of Immunobiology, King’s College, London, UK; 3Dental
Institute, King’s College, London, UK
Background: Tertiary Lymphoid Structures (TLSs) are common
features of chronic inflammatory diseases including Sjogren’s syn-
drome (SS). We recently showed that these ectopic structures acquire
secondary lymphoid organs properties and are capable of supporting
B cell activation and autoantibody production including expression of
activation-induced cytidine deaminase (AID) and Ig class switching.
Dissecting TLSs dynamics in humans is technically and ethically
challenging. Thus, we used the NOD mouse, a spontaneous model of
autoimmune sialoadenitis, to characterize the cellular and molecular
basis of autoreactive B cell activation and evolution of functional
Ectopic Lymphoid Structures (ELS) in the chronically inflamed NOD
salivary glands.
Methods: Submandibular glands from 110 female NOD mice from 4 to
35 weeks of age were collected. Paired snap-frozen samples were
analysed by immunohistochemistry (IHC) for T and B lymphocytes
(CD3/CD20) to evaluate cell infiltration and the degree of B/T cell
segregation. ELS were detected by staining for FDC-M1 (follicular
dendritic cell networks), GL7 (germinal centre B cells) and AID (marker
for ELS functionality). Characterization of B cell subsets within the
infiltrates was carried out by immunostaining and by FACS analysis
with CD19, CD21, CD23, B220, IgD, IgM, CD1d and CXCR5
antibodies. Quantitative TaqMan real-time PCR was performed to
investigate the mRNA expression of ELS-related genes. Sex/age
matched Balb/c and C57BL/6 mice were used as controls.
Results: NOD infiltrates in glands displayed progressive features of
ELS from week 8, with 75% of mice developing B/T cell segregation,
FDC networks and GL7þ ectopic germinal centers from week 20.
Evolution of TLSs was closely associated with mRNA upregulation of
genes regulating ELS organization and function such as lymphoid
chemokines CXCL13/CCL19 and their receptors CXCR5/CCR7,
lymphotoxins and B cell survival factors BAFF and APRIL. In
agreement with CXCL13/CXCR5 mRNA expression, B cells in
infiltrates display strong CXCR5 expression and were mostly char-
acterized by a follicular phenotype (B220þ/IgDþ/IgMlow/CD23þ/
CD21low) as demonstrated by both IHC and FACS analysis on
isolated cells. Finally, functionality of ELS was demonstrated by
expression of AID mRNA and protein within FDC networks, which
paralleled the detection of circulating SS-related autoantibodies.
Conclusions: This work provided the first in-depth characterization of
cellular and molecular mechanisms underlying the evolution of
functional TLSs within submandibular infiltrates of NOD mice. These
data strongly support the hypothesis that B-cells can be activated
within TLSs in the target organ and promote in situ autoantibody
response. Overall, these data support the critical importance of ELS
formation in chronic autoimmune inflammation and identified NOD
mice as a suitable model to test therapeutic strategies aimed at
modulating B cell functionality.
Disclosure statement: All authors have declared no conflicts of
interest.
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OP66. INDIRECT COSTS ESTIMATION IN PRIMARY
SJO¨GREN’S SYNDROME
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Background: The aim of this study was to estimate the indirect costs,
such as loss of time from work, associated with primary Sjo¨gren’s
syndrome (pSS) compared with Rheumatoid Arthritis (RA) and
community controls.
Methods: Data were obtained from 84 female patients with pSS as
part of a study to develop a systemic activity measure, from 87
consecutive female patients with RA attending a hospital clinic and
from 96 female community controls on a general practice list. A
modified economic component of the Stanford Health Assessment
Questionnaire was used to assess lost productivity. Indirect costs
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